Relevant quote from the Holmstrom article
Posted: Mon Jan 18, 2021 8:48 pm
"The treatment of patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma with CART and bispecific T-cell engagers (BiTE) has shown remarkable results, with overwhelming response rates in heavily pre-treated patients [1,138]. These modalities target CD19, which is a surface molecule commonly expressed in several B-cell malignancies, and treatment with CD19-specific CART results in chronic B-cell aplasia in a substantial proportion of patients due to the cytotoxic killing of both tumor cells and B-cell precursors. Although this B-cell aplasia is problematic, patients can live with this condition. However, the treatment of MPN with CART and BiTE is challenging because no surface antigen has been shown to be genuinely expressed by the neoplastic cells. Targeting hematopoietic stem cell markers expressed by malignant cells in MPN, such as CD33 and CD34, would likely result in the killing of both neoplastic and normal hematopoietic stem cells and is thus precluded. Mutant CALR is expressed on the plasma membrane and binds the thrombopoietin receptor [17]. If this binding of mutant CALR to the thrombopoietin receptor is stable, the possibility of CALR-mutant-specific monoclonal antibodies might be worth exploring. An illustration of the potential different cytotherapeutic modalities for MPN is provided in Figure 4."
As you can see Car-t not happening anytime soon in MDS/MF. Targeting mutant CALR, very preliminary.
As you can see Car-t not happening anytime soon in MDS/MF. Targeting mutant CALR, very preliminary.